Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Merck and Company    MRK

MERCK AND COMPANY (MRK)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Merck and : Animal Health Extends Commitment to Fighting Rabies in the World's Most At Risk Regions

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/03/2017 | 01:45pm CEST

Release date- 02102017 - MADISON, N.J. - Today marks the midway milestone for World Rabies Day, when the Global Alliance for Rabies Control, together with health organizations from around the world, set a goal of eliminating human rabies transmitted by dogs by 2030.

Merck Animal Health (known as MSD Animal Health outside the United States and Canada) is pleased to announce our continued support in the fight against rabies through the donation of NOBIVACRabies vaccine and other resources to the Afya Serengeti Project and Mission Rabies, organizations working to eliminate this disease in the world's most at-risk regions.

Rabies, a neglected disease of vulnerable populations, is nearly 100 percent fatal but also nearly 100 percent preventable through canine vaccination. Africa and India still bear the highest burden of total annual rabies deaths.i Countries with the highest fatalities from rabies are India, Democratic Republic of the Congo, Ethiopia, China and Myanmar.ii

'Each year, an estimated 60,000 people die from rabies, with 40 percent of those deaths occurring in children under the age of fifteen,' said Ingrid Deuzeman, global marketing director, Merck Animal Health. 'We are resolved to continue our collaboration with the Afya Serengeti Project, which we've been committed to for more than 15 years, and with Mission Rabies, in support of the global health community goal to eliminate rabies.'

Progress in the Fight Against Rabies

In more than 20 participating countries, when pet owners and veterinarians choose NOBIVAC vaccines, it allows Merck Animal Health to donate rabies vaccine to Mission Rabies and the Afya Serengeti Project.

'Mission Rabies launched at the end of 2013 and to date we've delivered the NOBIVAC Rabies vaccine to 700,000 street dogs in some of the world's worst rabies hotspots. Our flagship projects are delivering amazing results with no human rabies cases having been reported in the Indian city of Ranchi, the State of Goa or the city of Blantyre in Malawi so far this year. It's incredible considering just a few years ago, a hospital in Blantyre (the Queen Elizabeth Central Hospital) was reporting the highest incidence of child rabies deaths from any single institution in the whole of Africa,' said Luke Gamble, founder, Mission Rabies. 'We are all driven to power Mission Rabies forward and without the support of Merck Animal Health NOBIVAC Rabies vaccine, we couldn't do what we do. The vaccine is saving lives amongst some of the poorest and most vulnerable people in the world and it's a privilege to be a part of this project with everyone.'

'The human toll of rabies is needless and tragic. However, over the past 20 years, we have shown that vaccination programs can reach enough dogs to eliminate rabies anywhere in the world,' said Professor Sarah Cleaveland, founder, Afya Serengeti Project. 'With continued support from Merck Animal Health and other collaborators, I believe we have the vaccine and the tools to achieve zero human deaths from dog rabies by 2030.'

Eliminating Rabies in India and Africa

Since 2013, Mission Rabies has set a goal to vaccinate dogs across rabies hotspots in India, where over a third of all human rabies deaths occur.iii Based on the program's success in India, Mission Rabies has expanded its offering to Africa.

Mission Rabies does more than just vaccinate hundreds of thousands of dogs against rabies each year. They go to schools and educate children in these communities, informing them of the seriousness of the disease. Children are the most affected by rabies because they play with dogs and don't understand how deadly rabies can be.

Using a fast-paced team of veterinarians and volunteers, Mission Rabies has so far vaccinated more than 505,000 dogs, trained 80 veterinarians, and educated more than 1,200,000 children about the risk of rabies.

Saving Lives in the Serengeti

The Afya Serengeti Project has prevented thousands of deaths in the Serengeti through the widespread vaccination of domestic dogs. Since the start of the program, the incidence of human rabies, rabies in dogs and rabid dog bites has dropped to an all-time low.iv Each year, over 600 dog rabies cases have been prevented and 23 human lives saved. The effective control of rabies through dog vaccination has also had benefits for wildlife, including endangered African wild dogs, which have become re-established in the Serengeti National Park for the first time since the population disappeared as a result of rabies outbreaks in the early 1990s. Understanding the importance of providing vaccinations to other at-risk areas, the Afya Project has extended to Kenya, Bangalore and the Pune region of India.

About Merck Animal Health

For more than a century, Merck, a leading global biopharmaceutical company, has been inventing for life, bringing forward medicines and vaccines for many of the world's most challenging diseases. Merck Animal Health, known as MSD Animal Health outside the United States and Canada, is the global animal health business unit of Merck. Through its commitment to the Science of Healthier Animals, Merck Animal Health offers veterinarians, farmers, pet owners and governments one of the widest range of veterinary pharmaceuticals, vaccines and health management solutions and services. Merck Animal Health is dedicated to preserving and improving the health, well-being and performance of animals. It invests extensively in dynamic and comprehensive R&D resources and a modern, global supply chain. Merck Animal Health is present in more than 50 countries, while its products are available in some 150 markets. For more information, visit www.merck-animal-health.com or connect with us on LinkedIn, Facebook and Twitter at @MerckAH.

Forward-Looking Statement of Merck & Co., Inc., Kenilworth, N.J., USA

This news release of Merck & Co., Inc., Kenilworth, N.J., USA (the 'company') includes 'forward-looking statements' within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company's management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company's patents and other protections for innovative products and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company's 2016 Annual Report on Form 10-K and the company's other filings with the Securities and Exchange Commission (SEC) available at the SEC's Internet site (www.sec.gov).

Contact:

Tel: 267-305-3558

(c) 2017 Electronic News Publishing -, source ENP Newswire

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MERCK AND COMPANY
04/19MERCK AND : P&G Boasts Better Bottom Line
AQ
04/19MERCK AND : Biothera Pharmaceuticals Presents Translational Data from Ongoing Cl..
AQ
04/19LEAP THERAPEUTICS : Presents Nonclinical and Clinical Data on DKN-01 at AACR 201..
AQ
04/19MERCK AND : AstraZeneca and Merck - Updated Overall Survival Data for LYNPARZA i..
AQ
04/19MERCK AND : KEYTRUDA plus Pemetrexed and Platinum Chemotherapy Reduced the Risk ..
AQ
04/19MERCK AND : KEYTRUDA Reduced the Risk of Disease Recurrence or Death by More tha..
AQ
04/18ASTRAZENECA : New protein complex sensitizes cancers to PARP inhibitors
AQ
04/17MERCK AND : SELLAS Life Sciences Reports Corporate Highlights, Advancements for ..
AQ
04/17BRISTOL MYERS SQUIBB : Topples After Merck Treatment Outperforms It In Lung Canc..
AQ
04/17MERCK AND : Advances Clean Energy Goals with Invenergy
PU
More news
News from SeekingAlpha
04/19Novartis Q1 results weigh on pharma stocks 
04/19DYNAVAX : Assessing The Underlying Fundamentals Of A Big Winner 
04/18I'm Buying Bristol-Myers Down Near 52-Week Lows 
04/18ASLAN Pharmaceuticals Updates U.S. IPO Plans 
04/183 THINGS IN BIOTECH, APRIL 17 : Lung Cancer Madness 
Financials ($)
Sales 2018 41 868 M
EBIT 2018 13 837 M
Net income 2018 8 758 M
Debt 2018 13 091 M
Yield 2018 3,30%
P/E ratio 2018 17,93
P/E ratio 2019 15,24
EV / Sales 2018 4,11x
EV / Sales 2019 3,94x
Capitalization 159 B
Chart MERCK AND COMPANY
Duration : Period :
Merck and Company Technical Analysis Chart | MRK | US58933Y1055 | 4-Traders
Technical analysis trends MERCK AND COMPANY
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 67,5 $
Spread / Average Target 14%
EPS Revisions
Managers
NameTitle
Kenneth C. Frazier Chairman, President & Chief Executive Officer
Robert M. Davis CFO & Executive Vice President-Global Services
Clark Golestani Chief Information Officer & Executive VP
Roy D. Baynes Chief Medical Officer
Thomas Henry Glocer Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
MERCK AND COMPANY4.71%158 813
JOHNSON & JOHNSON-6.57%342 627
PFIZER0.30%217 064
NOVARTIS-4.37%213 465
ROCHE HOLDING LTD.-12.15%193 887
AMGEN0.56%117 021